financetom
Business
financetom
/
Business
/
Magellan Financial hits highest in 22 months on earnings, partnership deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Magellan Financial hits highest in 22 months on earnings, partnership deal
Aug 14, 2024 11:05 PM

By Sherin Sunny

Aug 15 (Reuters) - Shares of Magellan Financial Group ( MGLLF )

surged to their highest level in 22 months after the

asset manager posted a 31% rise in its annual profit and

announced a deal to buy a minority stake in an investment

management firm.

The stock rose as much as 11.2% to A$10.01 to its highest

level since Oct. 19, 2022, and is among the top gainers on the

ASX 200 benchmark index.

The company posted a net profit after tax of A$238.8 million

($158.13 million) for the full year ending June 2024, up from

A$182.7 million from a year earlier on higher performance fees

and lower expenses at its funds management business.

Additionally, the company inked a strategic partnership with

Vinva Investment Management, an Australia-based global

investment management firm, to acquire a 29.5% stake in the

latter's parent entity, Vinva Holdings, for A$138.5 million.

The deal gives Magellan exclusive rights to distribute

Vinva's products and investment strategies through its global

distribution team.

Both parties also intend to collaborate on new product

initiatives in Australia and globally.

"It does add additional product that Magellan can distribute

globally and expand its existing phase quite significantly,"

said Jun Bei Liu, a portfolio manager at Tribeca Investment

Partners.

She attributed the jump in shares to the deal rather than

the higher results, which were largely in line with expectations

The company declared an interim dividend of 28.6 Australian

cents per share, down from 39.8 cents apiece.

($1 = 1.5101 Australian dollars)

(Reporting by Sherin Sunny in Bengaluru; Editing by Janane

Venkatraman

)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
World Kinect Corporation Completes Acquisition of Universal Weather and Aviation's Trip Support Services Business
World Kinect Corporation Completes Acquisition of Universal Weather and Aviation's Trip Support Services Business
Nov 5, 2025
MIAMI--(BUSINESS WIRE)-- World Kinect Corporation ( WKC ) today announced that it has completed its previously announced acquisition of the Trip Support Services (TSS) division of Universal Weather and Aviation. Universal Weather, headquartered in Houston, Texas, has been a pioneer in trip support services with deep expertise in international travel regulations, logistics, and supply chain management. Its trip support business...
Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens
Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens
Nov 5, 2025
Overview * Cytokinetics ( CYTK ) Q3 net loss widens to $306.2 mln, driven by debt conversion expense * Company reports Q3 revenue of $1.9 mln, up from $0.5 mln last year * Cytokinetics ( CYTK ) prepares for potential U.S. launch of aficamten pending FDA approval Outlook * Company expects EMA decision on aficamten MAA in 1H 2026 *...
Delaware judge says she will not block Metsera from ending Pfizer deal 
Delaware judge says she will not block Metsera from ending Pfizer deal 
Nov 5, 2025
WILMINGTON, Delaware, Nov 5 (Reuters) - A Delaware judge said on Wednesday she would reject a request by Pfizer ( PFE ) to temporarily block Metsera ( MTSR ) from terminating its takeover deal with Pfizer ( PFE ), allowing Metsera ( MTSR ) to proceed instead with a higher $10 billion deal from Novo Nordisk. ...
Jazz Pharmaceuticals Q3 revenue beats estimates
Jazz Pharmaceuticals Q3 revenue beats estimates
Nov 5, 2025
Overview * Jazz Pharmaceuticals ( JAZZ ) Q3 revenue grows 7% yr/yr, beating analyst expectations * Adjusted EPS for Q3 beats consensus, reflecting robust operational performance * Company narrows 2025 revenue guidance to $4.175 - $4.275 bln Outlook * Company narrows 2025 revenue guidance to $4.175 - $4.275 bln * Jazz Pharmaceuticals ( JAZZ ) expects top-line data from zanidatamab...
Copyright 2023-2026 - www.financetom.com All Rights Reserved